Armata Pharmaceuticals Inc. (ARMP)
NYSE: ARMPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ARMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $141.66M
- EPS (TTM)
- -$5.29
- Dividend yield
- None
- 52-week range
- 3.09 – 16.34
- Day range
- 3.72 – 4.07
- Volume / Avg
- 103.61K / 212.63K
- Beta
- —
- Shares outstanding
- 37.18M
- Next earnings
- Nov 11, 2026
52-week range
ARMP stock today
On Oct 7, ARMP ended the session at $3.81, shedding $0.04 (1.04%), versus the S&P 500's 0.22% decline. Trading was light, with 103.61K shares changing hands, about 49% of the average daily volume. At this level, ARMP sits near the bottom of its 52-week range of $3.09 to $16.34: 76.7% below the high, set on Oct 22, 2025 and 23.3% above the low.
ARMP is down 39.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 21.3%. Armata Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.29), so its P/E ratio is not meaningful. Armata Pharmaceuticals's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Armata Pharmaceuticals
Company profileArmata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Deborah L. Birx M.D.
- Headquarters
- Los Angeles, CA
- Employees
- 61
- Website
- armatapharma.com
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$17.50+359.32%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
Armata Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OTLKOutlook Therapeutics Inc. | 0.59 | +3.15% | $143.63M | vs ARMP |
| AVXLAnavex Life Sciences Corp. | 1.53 | -4.38% | $141.83M | vs ARMP |
| MOLNMolecular Partners AG ADR | 3.81 | +0.79% | $145.94M | vs ARMP |
| TLSATiziana Life Sciences Ltd. | 1.10 | -0.90% | $139.99M | vs ARMP |
| RNAAtrium Therapeutics Inc. | 7.93 | -0.75% | $135.65M | vs ARMP |
| CLLSCellectis S.A. ADR | 1.34 | -4.29% | $134.96M | vs ARMP |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs ARMP |
| VYGRVoyager Therapeutics Inc. | 2.47 | +0.41% | $152.20M | vs ARMP |
Indexes, lists and sector
Appears in lists
Armata Pharmaceuticals stock FAQ
What is Armata Pharmaceuticals's stock price today?
ARMP last traded at $3.81 as of Oct 7, 4:00 PM EDT, down 1.04% on the day. Prices are delayed at least 15 minutes.
Does Armata Pharmaceuticals pay a dividend?
No. Armata Pharmaceuticals does not currently pay a regular cash dividend.
When is Armata Pharmaceuticals's next earnings date?
Armata Pharmaceuticals is expected to report earnings on Wednesday, November 11, 2026.
Who is Armata Pharmaceuticals's CEO?
Dr. Deborah L. Birx M.D. is the chief executive officer of Armata Pharmaceuticals Inc., which has about 61 employees.
Has ARMP ever split its stock?
Yes. The most recent ARMP stock split was a 1-for-14 split on May 10, 2019, one of 4 splits on record.
What is the ARMP 52-week high?
The 52-week high for ARMP is $16.34 and the 52-week low is $3.09. The stock is currently 76.7% below its high.